Shreeram Agharkar, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 400 shares at $2.50 ($1K) on 2015-12-31, disclosed to the SEC on 2016-01-05.
Open-market purchase of $1k RLMD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.